30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q13 Revenue: RTI Biologics

$25.9MM, -10%

  • Sports Medicine $10.5MM, -22%
  • Spine $10MM, +18%
  • Bone Graft Substitutes/General Orthopaedic (BGS/GO) $5.3MM, -24%


  • Still feeling effects of FDA warning letter received in 4Q12
  • Added >100 new Sports Med accounts in quarter; expecting to regain former customers following resolution of warning letter
  • Spine growth supported by timing of orders from commercial partners
  • BGS/GO impacted by weaker than expected orders from large commercial distributor, customer reaction to warning letter
  • Anticipating 2013 launch of MAP3 (Multipotent Adult Progenitor) cellular allogeneic bone graft